SCHEMBL15840587

SCHEMBL15840587

CCCc1c(C)nc(Nc2nc(C)c3cccc(C)c3n2)[nH]c1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.52
USP2 O75604 2/20 0.52
TSHR P16473 2/20 0.52
ALDH1A1 P00352 4/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
KMT2A Q03164 3/20 0.52
HTT P42858 4/20 0.51
LMNA P02545 4/20 0.51
NPSR1 Q6W5P4 4/20 0.51
HSD17B10 Q99714 3/20 0.51
XBP1 P17861 2/20 0.51
STAT3 P40763 2/20 0.50
RAB9A P51151 2/20 0.48
MEN1 O00255 2/20 0.48
ALOX15 P16050 1/20 0.45
POLB P06746 2/20 0.44
GAA P10253 1/20 0.44
ALPL P05186 1/20 0.43
ALPI P09923 1/20 0.43
ALPG P10696 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15840784 0.87 MAPT (0.56) MAPTUSP2TSHRALDH1A1SMN1; SMN2
SCHEMBL15840687 0.85 ALDH1A1 (0.50) MAPTUSP2TSHRALDH1A1SMN1; SMN2
SCHEMBL15840690 0.85 ALDH1A1 (0.55) MAPTUSP2TSHRALDH1A1SMN1; SMN2
SCHEMBL15840753 0.84 STAT3 (0.71) MAPTUSP2TSHRALDH1A1SMN1; SMN2
SCHEMBL15840765 0.82 ALDH1A1 (0.52) MAPTUSP2TSHRALDH1A1SMN1; SMN2
SCHEMBL15840770 0.80 MAPT (0.62) MAPTUSP2TSHRALDH1A1SMN1; SMN2
SCHEMBL15840606 0.79 MAPT (0.67) MAPTUSP2TSHRALDH1A1SMN1; SMN2
SCHEMBL15840763 0.78 ALDH1A1 (0.62) MAPTUSP2TSHRALDH1A1SMN1; SMN2
SCHEMBL15840834 0.78 MAPT (0.68) MAPTUSP2TSHRALDH1A1SMN1; SMN2
SCHEMBL9879258 0.77 MAPT (0.62) MAPTUSP2TSHRALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB3 MAPT 1076/4885USP2 1628/4885TSHR 3057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.